Pazenir® (paclitaxel formulated as albumin bound nanoparticles) 5 mg/ml powder for dispersion for infusion: temporary supply shortage
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Pazenir
|
| Active substance |
paclitaxel
|
| Therapeutic area (MeSH) |
Breast Neoplasms
|
| Procedure number |
EMEA/H/C/004441
|
| DHPC type |
Medicine shortage
|
| Human ATC code |
L01CD01
|
| Dissemination date |
24/01/2023
|